All In Biotech

Free tool

FAERS Monitor: Edurant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202022 or its brand name (Edurant, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,915

Serious

1,297

68% of reports

Hospitalization

399

Death reported

87

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anxiety186
  • pain179
  • emotional distress156
  • anhedonia141
  • chronic kidney disease117
  • renal failure103
  • product dose omission issue100
  • viral load increased98
  • fatigue96
  • depression95
  • headache91
  • nausea76
  • rash67
  • foetal exposure during pregnancy63
  • osteoporosis63

Reports by year received

View as table
YearReports
20112
201216
201340
201442
2015109
2016125
201791
2018131
2019146
2020130
2021179
2022382
2023286
2024145
202560
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,244 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
viral load increasedSignal98284.4233.926,708
anhedoniaSignal14159.250.57,982
chronic kidney diseaseSignal11716.914.21,742
osteoporosisSignal6316.813.2924
emotional distressSignal15614.212.21,905
renal failureSignal1038.57.1680
foetal exposure during pregnancySignal638.56.7412
anxietySignal1867.26.3996
depressionSignal954.63.8266
product dose omission issueSignal1003.73.1200
painSignal1793.22.8277
rash671.71.318
headache911.61.320
fatigue961.41.19
nausea761.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.